Acquired deficiency of clotting factor VIII (FVIII ) is a rare bleeding diathesis seldom encountered in systemic lupus erythematosus (SLE ). Reduction of FVIII activity by autoantibodies can cause potentially life-threatening situations. Herein, an SLE patient with a positive lupus anticoagulant (LAC ) test who abruptly developed metrorrhagia 4 yr after diagnosis is reported. Coagulation tests revealed FVIII activity reduced to 3% and a prolonged aPTT. FVIII inhibitor(s) were found to be as high as 3.0 Bethesda Units. Plasmapheresis, immunoglobulins, prednisolone and FVIII plasma concentrates induced the cessation of metrorrhagia, but the clotting tests were barely improved. One month later, extensive ecchymosis appeared and worsened, despite re-administration of the previous therapy. Pulse cyclophosphamide followed by oral administration was then started with normalization of coagulation parameters and long-lasting disease remission.
Alloantibodies directed against factor VIII (FVIII )
ance of FVIII inhibitors was obtained only after adding cyclophosphamide to the combined therapy. occur in between 5 and 20% of patients affected by classic haemophilia (haemophilia A) treated with FVIII replacement therapy [1] . In systemic lupus erythDescription of the case ematosus (SLE), autoantibodies interfering with the functioning of FVIII occur with very low frequency: in A 19-yr-old woman with a 4 yr history of SLE came to the emergency room of our hospital due to a sudden metrorrhagia. a 10 yr survey, only 10 out of a total of 215 patients with FVIII autoantibodies had SLE in association [2] .
Four days before, she had had a similar episode that had required blood transfusion and oestrogen administration. On
Owing to the presence of these autoantibodies, FVIII function can be either completely altered (type I ), admission, she was also taking 12.5 mg/day of prednisolone. Gynaecological examination revealed the presence of clots in partially altered (type II ) or unchanged [3] . The therapeutic measures consist of a double strategy: stopping presence of FVIII inhibitor(s) at 2.8 Bethesda Units (BU )/ml.
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The values of factor IX (73%), factor XII (86%), vWRicof such as in our case. Nonetheless, one-third of the patients present amelioration of haemorrhages by means (60%), factor V (99%) and factor X (94%) were normal. LAC, detected by kaolin clotting time, was present. Anticardiolipin of spontaneous clearance of the inhibitors [6 ] .
Owing to the rarity of the cases, controlled therapy antibodies (ELISA), fibrin split products and the syphilis test ( VDRL) were negative.
trials are lacking, so the management of these patients is largely tentative. When reviewing 20 yr of literature,
Initial treatment consisted of plasmapheresis three times a week, prednisolone (50 mg/day i.v.) and one infusion of FVIII there was no consensus on the treatment of SLE associated with FVIII inhibitors. Corticosteroids were adminplasma concentrate (2000 IU ) which induced cessation of metrorrhagia within a week. However, the clotting tests did istered in SLE and Sjö gren's syndrome overlap [7] ; corticosteroids and 1-deamino-8--arginine vasopressin not become completely normal. The patient was discharged taking prednisolone 25 mg/b.i.d.
(DDAVP) in an SLE-like serology [8] ; combined immunosuppressive therapy with corticosteroids, azaOne month later, a massive haemorrhage recurred with ecchymosis on the lower limbs and hips, for which the patient thioprine, cyclophosphamide and cyclosporin followed by immunoglobulins in a case of SLE [9] ; corticosteroids was readmitted to hospital. Prednisolone (50 mg/day i.v.), gammaglobulins (0.4 g/kg/day i.v. for 3 days) and FVIII in a rheumatoid arthritis patient with positive LAC [4]; corticosteroids and cyclophosphamide to treat an overplasma concentrate (3000 IU/day for 2 days) were started. Despite the treatment, the ecchymosis worsened, along with a lap between mixed connective tissue disease and SLE [10] ; tranexamic acid and corticosteroids post-partum progressive decline of the Hb down to 7.7 g/dl. In following check-ups, FVIII activity ranged between 3 and 14%. Pulse with anti-DNA antibodies [11] ; immunoglobulins, cyclophosphamide and cyclosporin in SLE [12] ; plasmacyclophosphamide (750 mg/m2 i.v.) was then started and followed by an oral dose of 100 mg/day. Both clinical and pheresis, corticosteroids, cyclophosphamide, methotrexate, immunoglobulins and vincristine in two SLE laboratory improvement were evident after~2 weeks. Once discharged, the patient underwent combined therapy with patients [13] . Notably, in our case, corticosteroids, plasmapheresis and FVIII plasma concentrates halted the bleeding with only a partial improvement of the laboratory tests. Disappearance of the circulating FVIII inhibitor(s) disappeared after 1 month (Fig. 1) . Menses started again. After 1 month of therapy, cyclophosphamide was inhibitor(s) and normalization of the clotting tests were noticed only after adding cyclophosphamide. therapy and the risk of a new emergency. Looking at our and other cases in the literature, it seems that the best approach is to monitor both inhibitors and activity Discussion of FVIII sequentially, in order to demonstrate their divergent progression with time. We feel that neither the In autoimmune diseases, haemorrhages are a significant cause of morbidity and mortality for several reasons.
disappearance of bleeding nor the low titre of inhibitors per se have a trustworthy prognostic role in excluding a Firstly, the acquired haemophiliac, unlike hereditary haemophiliacs, is unprepared for haemorrhagic episodes.
relapse. In our case, repeated measurements always detected a low titre (3.0 BU ) of circulating inhibitor(s), Secondly, a sudden major bleeding can be the first symptom revealing the presence of a circulating antibut bleeding definitively stopped after the steady progressive enhancement of FVIII. This observation also coagulant(s). Thirdly, the cause of the bleeding may be further complicated, especially in SLE, by the overlapsupports the hypothesis that a low titre of the inhibitor(s) is related to responsiveness to immunosuppressive ping of different types of coagulant inhibitors [4, 5] , treatment [14] .
In conclusion, even a low titre of FVIII inhibitor(s) must keep clinicians alert until FVIII activity progressively increases. The reciprocal progression over time of FVIII and its inhibitor could identify cases in which cyclophosphamide is regarded as first-line treatment.
